CEBPA and acute myeloid leukemia: However, the mutation in CEBPA and Ras were highly infrequent in FLT3-ITD AML (2/52 (3.8%) vs. 26/131 (19.8%), P = 0.007; 1/52(1.9%) vs. 27/131(20.6%), P = 0.002).